Quick Answer
HALOZYME THERAPEUTICS, INC. reported Stockholders Equity of $48.81 million for the year ending 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -86.6% in Stockholders Equity from 2024 to 2025.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: $69.23 million | Q3 2012: $51.19 million | Q1 2013: $31.68 million | Q2 2013: $11.14 million | Q3 2013: -$3.49 million | Q1 2014: $66.75 million | Q2 2014: $55.30 million | Q3 2014: $39.94 million | Q1 2015: $37.55 million | Q2 2015: $50.23 million | Q3 2015: $31.80 million | Q1 2016: $29.47 million | Q2 2016: $9.92 million | Q3 2016: -$11.99 million | Q1 2017: -$58.50 million | Q2 2017: $58.17 million | Q3 2017: $72.39 million | Q1 2018: $265.06 million | Q2 2018: $254.92 million | Q3 2018: $239.74 million | Q1 2019: $260.05 million | Q2 2019: $260.05 million | Q3 2019: $245.35 million | Q1 2020: $58.04 million | Q2 2020: $105.58 million | Q3 2020: $98.99 million | Q1 2021: $67.60 million | Q2 2021: $119.75 million | Q3 2021: $281.67 million | Q1 2022: $260.26 million | Q2 2022: $293.17 million | Q3 2022: $96.99 million | Q1 2023: $65.85 million | Q2 2023: $151.03 million | Q3 2023: $249.18 million | Q1 2024: $177.81 million | Q2 2024: $289.42 million | Q3 2024: $452.70 million | Q1 2025: $482.27 million | Q2 2025: $332.75 million | Q3 2025: $503.92 million.
- Over the full 14 years of available data (2012 to 2025), HALOZYME THERAPEUTICS, INC.'s Stockholders Equity has declined by 0.1%.
- Historical annual values: Fiscal year 2025: $48.81 million | Fiscal year 2024: $363.82 million | Fiscal year 2023: $83.81 million | Fiscal year 2022: $169.80 million | Fiscal year 2021: $196.95 million | Fiscal year 2020: $151.05 million | Fiscal year 2019: $91.77 million | Fiscal year 2018: $248.89 million | Fiscal year 2017: $208.37 million | Fiscal year 2016: -$32.48 million | Fiscal year 2015: $43.00 million | Fiscal year 2014: $41.35 million | Fiscal year 2013: -$19.99 million | Fiscal year 2012: $48.86 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: